KR102498741B1 - 질환 치료용 이-치환된 피라졸 화합물 - Google Patents

질환 치료용 이-치환된 피라졸 화합물 Download PDF

Info

Publication number
KR102498741B1
KR102498741B1 KR1020187033931A KR20187033931A KR102498741B1 KR 102498741 B1 KR102498741 B1 KR 102498741B1 KR 1020187033931 A KR1020187033931 A KR 1020187033931A KR 20187033931 A KR20187033931 A KR 20187033931A KR 102498741 B1 KR102498741 B1 KR 102498741B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
cancer
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033931A
Other languages
English (en)
Korean (ko)
Other versions
KR20190003608A (ko
Inventor
조엘 허프
모토나리 우에스기
존 킨케이드
Original Assignee
에프지에이치 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프지에이치 바이오테크 인코포레이티드 filed Critical 에프지에이치 바이오테크 인코포레이티드
Publication of KR20190003608A publication Critical patent/KR20190003608A/ko
Application granted granted Critical
Publication of KR102498741B1 publication Critical patent/KR102498741B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020187033931A 2016-04-29 2017-04-28 질환 치료용 이-치환된 피라졸 화합물 Active KR102498741B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330049P 2016-04-29 2016-04-29
US62/330,049 2016-04-29
PCT/US2017/030261 WO2017190086A1 (en) 2016-04-29 2017-04-28 Di-substituted pyrazole compounds for the treatment of diseases

Publications (2)

Publication Number Publication Date
KR20190003608A KR20190003608A (ko) 2019-01-09
KR102498741B1 true KR102498741B1 (ko) 2023-02-10

Family

ID=59215955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033931A Active KR102498741B1 (ko) 2016-04-29 2017-04-28 질환 치료용 이-치환된 피라졸 화합물

Country Status (12)

Country Link
US (2) US11497738B2 (https=)
EP (1) EP3448851B8 (https=)
JP (1) JP6931695B2 (https=)
KR (1) KR102498741B1 (https=)
CN (1) CN109476635B (https=)
AU (1) AU2017258781C1 (https=)
CA (1) CA3022395C (https=)
ES (1) ES2912921T3 (https=)
IL (1) IL262708B (https=)
MX (1) MX382630B (https=)
WO (1) WO2017190086A1 (https=)
ZA (1) ZA201807509B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2932187T3 (es) 2016-09-07 2023-01-16 Fgh Biotech Inc Compuestos de pirazol disustituidos para el tratamiento de enfermedades
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
EP3746070A4 (en) * 2018-01-29 2021-09-01 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A 6-LINKED CENTER RING
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN114728909A (zh) * 2019-09-25 2022-07-08 韩国原子力医学院 含有新型三氟甲基苯基吡唑衍生物作为活性成分用于预防或治疗癌症的组合物
KR102663365B1 (ko) * 2019-09-25 2024-05-08 한국원자력의학원 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
EP4096659A4 (en) * 2020-01-27 2023-10-18 Capulus Therapeutics, LLC Srebp inhibitors comprising a thiophene central ring
KR102258451B1 (ko) * 2020-11-17 2021-05-31 주식회사 하이센스바이오 지방간질환의 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062737A2 (en) 2000-02-24 2001-08-30 Ortho-Mcneil Pharmaceutical, Inc. Amino pyrazole derivatives useful for the treatment of obesity and other disorders
WO2016105491A1 (en) * 2014-12-23 2016-06-30 Fgh Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
CZ284157B6 (cs) 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP3303044B2 (ja) 1994-12-21 2002-07-15 エヌイーシートーキン株式会社 永久磁石とその製造方法
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE407132T1 (de) 2000-12-05 2008-09-15 Vertex Pharma Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
AU2003216581A1 (en) * 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
ES2379076T3 (es) 2002-12-02 2012-04-20 Astellas Pharma Inc. Derivados de pirazol útiles como inhibidores de COX-I
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
RU2005134670A (ru) 2003-04-10 2006-06-10 Аванир Фармасьютикалс (Us) Производные имидазола для лечения аллергических и гиперпролиферативных нарушений
WO2005044194A2 (en) 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
EP1789498A1 (en) 2004-09-02 2007-05-30 Clariant International Ltd. Use of thiazolyl-pyridinium dyes for optical data recording
EP2402323A3 (en) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
AU2006210503B2 (en) 2005-02-03 2009-09-03 Irm Llc Compounds and compositions as PPAR modulators
CN101203220A (zh) 2005-06-28 2008-06-18 阿斯利康(瑞典)有限公司 新用途
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US20160221999A1 (en) 2007-02-02 2016-08-04 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
JP5461197B2 (ja) 2007-02-02 2014-04-02 ベイラー カレッジ オブ メディスン 代謝障害を処置するための組成物および方法
DE102007040243A1 (de) 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
CN101918389A (zh) 2007-11-02 2010-12-15 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
TWI453019B (zh) * 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
GB0806794D0 (en) 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds
WO2011038261A1 (en) 2009-09-24 2011-03-31 Selexagen Therapeutics, Inc. Heterocyclic kinase inhibitors
JP5640091B2 (ja) 2009-10-01 2014-12-10 カディラ・ヘルスケア・リミテッド 脂質異常症および関連疾患の治療のための化合物
CN102933079B (zh) 2010-03-04 2016-02-17 默沙东公司 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途
WO2011133444A1 (en) 2010-04-21 2011-10-27 Merck Sharp & Dohme Corp. Substituted pyrimidines
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
BR112014006940A2 (pt) * 2011-09-23 2017-04-04 Bayer Ip Gmbh uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas
SI3038622T1 (en) 2013-08-28 2018-08-31 Medivation Technologies Llc Heterocyclic compounds and methods of use
WO2015031710A1 (en) 2013-08-29 2015-03-05 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
AU2014345594B2 (en) * 2013-11-05 2018-11-08 Elanco Animal Health Gmbh Substituted benzamides for the treatment of arthropods
EP3096761A1 (en) 2014-01-24 2016-11-30 Confluence Life Sciences, Inc. Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
WO2016073826A1 (en) 2014-11-07 2016-05-12 Fgh Biotech, Inc. Synthesis of fatostatin based polycyclic compounds
AU2015369712B2 (en) 2014-12-22 2020-05-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
EP3265457A1 (en) 2015-03-04 2018-01-10 Medivation Technologies LLC Sterol regulatory element-binding proteins (srebps) inhibitors
US10183015B2 (en) 2015-03-04 2019-01-22 Medivation Technologies Llc Heterocyclic compounds and methods of use
CN105294584A (zh) 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
ES2932187T3 (es) 2016-09-07 2023-01-16 Fgh Biotech Inc Compuestos de pirazol disustituidos para el tratamiento de enfermedades

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062737A2 (en) 2000-02-24 2001-08-30 Ortho-Mcneil Pharmaceutical, Inc. Amino pyrazole derivatives useful for the treatment of obesity and other disorders
WO2016105491A1 (en) * 2014-12-23 2016-06-30 Fgh Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
MX2018013221A (es) 2019-06-24
ZA201807509B (en) 2022-04-28
US20190134017A1 (en) 2019-05-09
EP3448851B8 (en) 2022-04-27
AU2017258781A1 (en) 2018-11-22
MX382630B (es) 2025-03-13
ES2912921T3 (es) 2022-05-30
RU2018138054A3 (https=) 2020-07-15
KR20190003608A (ko) 2019-01-09
CN109476635B (zh) 2021-07-13
WO2017190086A1 (en) 2017-11-02
AU2017258781B2 (en) 2021-09-02
CA3022395C (en) 2024-11-05
EP3448851B1 (en) 2022-03-23
US20230119547A1 (en) 2023-04-20
JP6931695B2 (ja) 2021-09-08
JP2019515956A (ja) 2019-06-13
AU2017258781C1 (en) 2022-03-03
IL262708B (en) 2022-04-01
US11497738B2 (en) 2022-11-15
NZ747987A (en) 2025-05-30
RU2018138054A (ru) 2020-05-29
CA3022395A1 (en) 2017-11-02
EP3448851A1 (en) 2019-03-06
CN109476635A (zh) 2019-03-15
IL262708A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
KR102498741B1 (ko) 질환 치료용 이-치환된 피라졸 화합물
EP2358371B1 (en) P2x3, receptor antagonists for treatment of pain
TWI694076B (zh) 三唑并嘧啶化合物及其用途
CN110072861B (zh) 用于治疗疾病的二取代吡唑类化合物
WO2017149463A1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
AU2014234909B2 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
JP2017537948A (ja) Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体
EP3617195B1 (en) Novel tetrahydronaphthyl urea derivatives as inhibitors of tropomyosin receptor kinase a for the treatment of pain
TW202400593A (zh) Ｍｙｓｔ家族離胺酸乙醯轉移酶之抑制劑
CN111093658A (zh) 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
JP7736712B2 (ja) Ｎａｍｐｔモジュレーター
CN117143039B (zh) 一种苯并五元氮环类化合物、其制备方法及医药用途
RU2772212C2 (ru) Двухзамещенные соединения пиразола для лечения заболеваний
CA3036195C (en) Di-substituted pyrazole compounds for the treatment of diseases
KR20260029377A (ko) 암 및 염증성 질환 치료에 사용하기 위한 이미다조[1,2-α]피리딘 화합물 및 그 화합물의 제조 방법
TW201910325A (zh) 吲哚衍生物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200427

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220125

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220729

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220325

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200427

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221202

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20221101

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220729

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220325

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200427

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230208

End annual number: 3

Start annual number: 1

PG1601 Publication of registration